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ABSTRACT 
BACKGROUND: A multitude of risk/protective factors for anxiety and obsessive-
compulsive disorders have been proposed. We conducted an umbrella review to 
summarize the evidence of the associations between risk/protective factors and each of 
the following disorders: specific phobia, social anxiety disorder, generalized anxiety 
disorder, panic disorder, and obsessive-compulsive disorder (OCD), and to assess the 
strength of this evidence whilst controlling for several biases.  METHODS:  
Publication databases were searched for systematic reviews and meta-analyses 
examining associations between potential risk/protective factors and each of the 
disorders investigated. The evidence of the association between each factor and 
disorder was graded into convincing, highly suggestive, suggestive, weak, or non-
significant according to a standardized classification based on: number of cases 
(>1000), random-effects p-values, 95% prediction intervals, confidence interval of the 
largest study, heterogeneity between studies, study effects, and excess of significance. 
RESULTS: Nineteen systematic reviews and meta-analyses were included, 
corresponding to 216 individual studies covering 427 potential risk/protective factors. 
Only one factor association (early physical trauma as a risk factor for social anxiety 
disorder, OR=2.59, 95% CI: 2.17-3.1) met all the criteria for convincing evidence. 
When excluding the requirement for more than 1000 cases, five factor associations 
met the other criteria for convincing evidence and 22 met the remaining criteria for 
highly suggestive evidence. CONCLUSIONS: Although the amount and quality of 
the evidence for most risk/protective factors for anxiety and obsessive-compulsive 
disorders is limited, a number of factors significantly increase the risk for these 
disorders, may have potential prognostic ability and inform prevention.  
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INTRODUCTION 
Anxiety disorders are the most common group of mental disorders and are associated 
with enormous societal costs (Kessler et al. 2010; Craske & Stein 2016). Both 
“genetic” and “non-genetic” (i.e., environmental) variables (as well as their 
interaction) have been proposed as potential risk/protective factors for anxiety 
disorders (Craske et al. 2017), although such a distinction may be somewhat artificial, 
given that many risk/protective factors include both genetic and non-genetic 
components. 
 
The evidence on risk/protective factors for anxiety disorders has been 
summarized in several systematic reviews and meta-analyses. However, findings are 
conflicting and there have been no previous attempts to summarize in a single report 
the strength of the evidence for the different potential risk/protective factors for each 
anxiety disorder or to assess possible biases in the literature. 
We present the results of an umbrella review of risk/protective factors for the 
most common anxiety disorders. We will focus on specific phobia, social anxiety 
disorder (SAD), generalized anxiety disorder (GAD), panic disorder (PD), and 
obsessive-compulsive disorder (OCD) ––the latter having been classified as an anxiety 
disorder until the publication of the 5
th
 edition of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5; American Psychiatric Association 2013). Umbrella 
reviews systematically collect and assess the existing evidence from individual studies 
included in systematic reviews and/or meta-analyses and have an increasing role in 
evidence-based health care and evidence-based assessments (Ioannidis 2009; Fusar-
Poli & Radua 2018).  
In the current absence of valid biomarkers or clear mechanistic explanations 
for most mental disorders (Kapur et al. 2012), the identification of putative (and, at 
least for some, modifiable) risk/protective factors may lead to the development of 
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more efficient risk prediction models, and may offer clues for prevention and 
treatment (Paulus 2015; Moreno-Peral et al. 2017; Fusar-Poli et al. 2018). Our aim 
was to systematically assess the amount of evidence and the robustness of associations 
between potential risk/protective factors and each of the aforementioned disorders.  
 
METHODS 
We conducted an umbrella review (Ioannidis 2009; Fusar-Poli & Radua 2018) to 
assess the relation between potential risk/protective factors and anxiety and obsessive-
compulsive disorders. We followed the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al. 2009) and the Meta-
analysis of Observational Studies in Epidemiology (MOOSE) guidelines (Stroup et al. 
2000) (Tables S1 and S2 in the supplementary material). The study protocol was pre-
registered with the International Prospective Register of Systematic Reviews 
(PROSPERO; CRD42017060090). 
 
Search strategy and eligibility criteria 
We searched PubMed, Web of Science, and Scopus from inception to April 30, 2018 
for systematic reviews and meta-analyses of observational studies examining 
associations between potential risk/protective factors (see below) separately for each 
disorder. The search strategy used the keywords "systematic review" or "meta-
analysis" and each of the disorders of interest. We also hand searched the reference 
lists of all systematic reviews and meta-analysis reaching full-text review. 
Eligibility criteria were: 1) a systematic review or meta-analysis of 
risk/protective factors for specific phobia, SAD, GAD, PD, or OCD as defined in any 
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edition of the International Classification of Diseases (ICD) manual or the DSM; 2) 
inclusion of a healthy comparison group; and 3) studies reporting sufficient data (or 
that were retrievable after contacting the authors) to perform the analyses. We did not 
apply any language restrictions in the selection of systematic reviews or meta-
analyses.  
Even though we had hoped to include molecular genetic studies in the umbrella 
review, we found that the literature for the disorders investigated is dominated by 
candidate gene studies, which are known to have low credibility. Such risk factor 
assessment should await thus the publication of large genome-wide studies (Ioannidis 
et al. 2008). Moreover, different analytical methods and assessment criteria are 
required for umbrella reviews of genetic variables (Ioannidis et al. 2008). 
 Although in some DSM classifications previous to DSM-5 “panic disorder” 
and “panic disorder with agoraphobia” have been classified separately, we included 
both in our “panic disorder” category. However, we have analyzed them separately 
where a study reported separate factors for each of these categories. We also 
considered separation anxiety disorder and selective mutism (“anxiety disorders” in 
the DSM-5), but they were not included due to the lack of systematic reviews and 
meta-analyses (Figures S6 and S7). Posttraumatic stress disorder (PTSD), grouped as 
an anxiety disorder until the publication of DSM-5, will be covered in a separate 
manuscript.  
Further information about the search strategy and the eligibility criteria can be 
found in the supplementary material. 
 
Risk/protective factor definition 
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We used the following definition of risk factor: "that characteristic, variable, or hazard 
preceding the outcome of interest that, if present for a given individual, makes it more 
likely that this individual, rather than someone selected from the general population, 
will develop a given disorder" (Mrazek & Haggerty 1994; Kraemer et al. 1997). 
Similarly, protective factors are those where risk is found to be decreased. We 
assessed both stable factors (e.g., sex), for which time precedence does not need to be 
established, and factors that are subject to change within-subject. For the latter, we 
required that the determination of the factor preceded the diagnosis of the outcome 
(i.e., the disorder) even if the information on the factor and the outcome was collected 
at the same time point (as in the case of cross-sectional studies). This rule ensured that 
there would be time precedence for the assessments of factors and outcomes, although 
factors may have existed even before their determination, and disorders may have also 
existed before their diagnosis. Furthermore, when the factor investigated was related 
to personality dimensions (e.g., neuroticism), we also required that personality was 
assessed before the disorder was diagnosed in order to avoid state-trait influences 
(Reich et al. 1987). The definitions for each factor were those given in the 
corresponding systematic review or meta-analysis. 
  Following previous work (Radua et al. 2018) we grouped factors into several 
descriptive categories: sociodemographic, psychopathology, parental 
psychopathology, personality dimensions, substance use, life events, perinatal 
complications, parental rearing styles/attachment, and others. 
 
Data extraction and selection 
We used a systematic approach to extract and select the data. First, we identified the 
factors assessed in each systematic review or meta-analysis. Second, two investigators 
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independently checked that each individual article included in the systematic review or 
meta-analysis met the same eligibility criteria applied to the systematic review or 
meta-analysis. Third, two investigators independently extracted the following data 
(from the systematic review or meta-analysis or, in most cases, from the individual 
studies): first author and year of publication; number of cases and controls; measure 
and size of the risk and corresponding 95% confidence intervals (CIs); specific 
variables depending on the measure of effect size; and whether the study was a 
prospective cohort. Specific variables depending on the measure of effect size were: 
number of cases and person-times in exposed and unexposed for incidence rate ratios 
(IRR), number of cases and total number of exposed and unexposed for risk ratios 
(RR), number of exposed and unexposed and cases and controls for odds ratios (OR), 
and means and standard deviations for cases and controls for standardized mean 
differences (SMD). Fourth, two investigators independently rated the quality of the 
systematic review or meta-analysis using the Assessment of Multiple Systematic 
Reviews (AMSTAR; Shea et al. 2007) tool, with substantial interrater agreement (both 
weighted Cohen’s kappa and intraclass correlation = 0.71; see Supplementary 
Material). A third investigator reviewed the extracted data to check for 
inconsistencies, and disagreements were resolved by consensus. For further details on 
the data extraction, selection, and quality assessment, see the supplementary material.  
 
Statistical analysis 
We performed statistical analyses commonly used in standard meta-analyses. 
However, we did not use the statistics provided in the included systematic review or 
meta-analyses because there are differences across-studies in the methods employed 
and because some analyses are often not conducted (e.g., the test for an excess of 
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significant findings). 
We conducted a separate random-effects meta-analysis for each factor and 
disorder. The outcomes of the meta-analyses were the effect sizes with their CIs and p-
values, and the statistics required to assess the level of evidence (see below). 
Depending on the factor, we used IRR, RR, OR, or SMD Hedges’ g. For descriptive 
purposes, we also report OR equivalents (eOR) of IRR, RR, and Hedge’s g (see Fusar-
Poli & Radua (2018) for additional details).   
We assessed between-study heterogeneity by estimating the 95% prediction 
interval – which evaluates the uncertainty for the effect that would be expected in a 
new study addressing that same association – and the I2 metric (Ioannidis et al. 2007). 
I
2 
> 50% were considered to represent substantial heterogeneity (Higgings & Green 
2009). We also assessed whether there was evidence of small-study effects with Egger 
tests (Egger et al. 1997), where statistical significance would mean potential reporting 
or publication bias in the smaller studies. Finally, excess significance (a relative excess 
of statistically significant findings) was assessed with a binomial test that compared 
the observed vs the expected number of studies yielding statistically significant results 
(Radua et al. 2018). 
The levels of evidence of the associations between each factor and disorder 
were classified into convincing (class I), highly suggestive (class II), suggestive (class 
III), or weak (class IV) (Fusar-Poli & Radua 2018). Convincing evidence required a 
number of cases (n) >1000, a highly significant association (p<10
-6
), I
2
<50%, a 
statistically significant 95% prediction interval, and the absence of small-study effects 
and excess significance bias. Highly suggestive evidence also required n >1000, a 
highly significant association (p<10
-6
), and that the largest study had a statistically 
significant effect. Suggestive evidence required n >1000 and p<10
-3
. Weak evidence 
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required no specific number of cases and p<0.05. Furthermore, after collecting all the 
available evidence, we noticed that, with few exceptions, there were fewer than 1000 
cases for most factors. Therefore, we also examined these criteria removing the 
requirement of n >1000, so as to obtain a more fine-grained appraisal of the evidence. 
For associations with significant evidence (classes I-IV), we also conducted a 
sensitivity analysis by using only prospective cohort studies. 
 
RESULTS 
We included 19 systematic reviews and meta-analyses (Figure 1 and Figures S1-S5 in 
the supplementary material). AMSTAR scores are presented in Table 1. All extracted 
data and results are available at: 
https://www.umbrellaevidence.com/anxiety/riskfactors/. 
 We extracted data for 427 factors from 216 individual studies. The number of 
systematic reviews and meta-analyses, individual studies assessed and included, and 
factors included are presented in Table 2. The groups of factors assessed in each 
systematic review or meta-analysis are reported in Table 1 and the specific factors in 
Table S3 (see supplementary material). Factors showing convincing, highly 
suggestive, or suggestive evidence of association with each disorder are presented in 
Table 3. All significant factors (including those showing weak evidence of 
association) are presented in Table S4 (see supplementary material).  
 Overall, the number of cases was greater than 1000 for 20 factors (4.68%). 
One-hundred eighty-three of the 427 factors (42.84%) presented a statistically 
significant effect (p<0.05) under the random-effects model, but only 91 (21.31%) had 
a p<0.005 and only 27 (6.32 %) reached p<10
-6
. Twenty-five factors (36.76%) 
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presented a large estimate of heterogeneity (I
2
>50%), while for 29 factors (78.37%) 
the 95% prediction interval did not include the null. Additionally, evidence for small-
study effects and excess significance bias was noted for 2 (5.40%) and 8 (1.87%) 
factors, respectively (see Table S4 in the supplementary material).   
 
Results by disorder 
Specific phobia 
No factor showed convincing or highly suggestive evidence as a risk/protective factor 
for specific phobia using the original umbrella review criteria. Removing the n>1000 
criterion, being male showed convincing evidence as protective factor. Moreover, 
neuroticism showed highly suggestive evidence as risk factor for the disorder, which 
was maintained after the sensitivity analyses (Table 3, Figure 2, and Table S4).  
 
Social anxiety disorder  
Early physical and sexual trauma showed, respectively, convincing and suggestive 
evidence as risk factors for SAD. Additionally, when removing the n>1000 criterion, 
dysthymia, insecure attachment in childhood, major depression, and neuroticism 
showed highly suggestive evidence as risk factors for SAD. After sensitivity analyses, 
evidence for both trauma-related factors became weak, but the rest of factors–except 
insecure attachment in childhood- maintained the same level of evidence (Table 3, 
Figure 2, and Table S4). 
 
Generalized anxiety disorder 
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No factor showed convincing or highly suggestive evidence as a risk/protective factor 
for GAD. Removing the n>1000 criterion, being male showed convincing evidence as 
protective factor for GAD and the following factors showed highly suggestive 
evidence as risk factors for the disorder: psychological malaise at age 33, borderline 
personality disorder, parental GAD without comorbidity, early physical and sexual 
trauma, and behavioral inhibition (assessed as a personality dimension). After 
sensitivity analyses, all these factors – except both trauma-related variables – 
maintained the same level of evidence (Table 3, Figure 2, and Table S4). 
 
Panic disorder 
No factor showed convincing or highly suggestive evidence as risk/protective factor 
for PD. Removing the n>1000 criterion, being male, separation anxiety in childhood, 
and early physical trauma showed convincing evidence as risk/protective factors for 
PD. The evidence was not maintained, however, after sensitivity analyses. 
Furthermore, daily cigarette smoking, panic attacks, and major depression showed 
highly suggestive evidence as risk factors for PD, which was maintained after 
sensitivity analyses (Table 3, Figure 2, and Table S4). 
 
Obsessive-compulsive disorder 
No factor showed convincing or highly suggestive evidence as risk/protective factor 
for OCD. Removing the n>1000 criterion, several parental rearing style variables, 
neuroticism, and use of cocaine together with another drug (except marijuana) showed 
highly suggestive evidence as risk/protective factors for OCD. However, the latter was 
based on a single study reporting one single case in the exposed group. Only 
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neuroticism and use of cocaine together with another drug (except marijuana) 
maintained the same level of evidence after the sensitivity analyses (Table 3, Figure 
2, and Table S4). 
 
DISCUSSION 
This is, to the best of our knowledge, the first umbrella review of risk/protective 
factors for anxiety and obsessive-compulsive disorders. Our study provides a state-of-
the-art classification of risk/protective factors based on the robustness of associations 
between these factors and five separate disorders, while controlling for several biases.  
Using the original umbrella review criteria, early physical trauma was the single 
most consistent risk factor – class I – for SAD. Early sexual trauma was also 
associated – class III –with SAD. Several “traditional” risk/protective factors for 
anxiety and obsessive-compulsive disorders were among those that had nominally 
statistically significant results (Beesdo et al. 2009; Craske & Stein 2016). Although we 
could not assess exactly the same factors for all disorders, a number of factors showed 
a similar association with several of the disorders investigated (Figure 3). For 
example, being male was associated with decreased risk for specific phobia, SAD, 
GAD, and PD; and neuroticism was associated with increased risk for specific phobia, 
SAD, GAD, and OCD. Moreover, early traumatic experiences increased the risk of all 
disorders in which they were investigated (SAD, GAD, PD, and OCD). Although the 
evidence for most of these associations was rated as weak, the consistency of these 
signals across multiple disorders strengthens the case that they do carry prognostic 
potential. The fact that the same factors increased the risk for different disorders may 
indicate a shared liability within anxiety and obsessive-compulsive disorders (Blanco 
et al. 2014). Moreover, some factors may be shared across mental disorders (i.e., be 
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“transdiagnostic”). For example, early traumatic experiences are a significant risk 
factor for depressive (Köhler et al. 2018), psychotic (Belbasis et al. 2018; Radua et al. 
2018), and bipolar disorders (Bortolato et al. 2017).  Importantly, the results of our 
umbrella review provide hints not only on the presence/absence of a particular factor 
but also on the loading (weight) of that factor, which may be still unique (Uher & 
Zwicker 2017). 
The non-specificity of the findings for most risk factors investigated here (and 
probably for most risk factors for mental disorders in general) may also be partially 
explained by the fact that developmental effects (including temporal dynamics and the 
development of comorbidity over time)  are often ignored in current nosological 
systems. The use of longitudinal "staging models" – that describe the progression from 
more simple or "pure" disorders to more complex or comorbid disorders – has been 
proposed to deal with these issues. Such models could offer a better description of the 
developmental patterns typical to most mental disorders (Beesdo et al. 2009). 
Our data suggest that rather than “a few” risk or protective factors with large 
effects, large sets of common “variants” of small effects account for the risk for 
anxiety and obsessive-compulsive disorders. This idea, which is well established in 
psychiatry genetics (Anttila et al. 2018; Sullivan et al. 2018), seems to be also true for 
“non-purely genetic” factors (Uher & Zwicker 2017). Furthermore, our findings open 
the door to the potential development of enhanced risk prediction models (Bernardini 
et al. 2017) and individual risk prediction scores (see Kessler et al., 2014, and Shalev 
et al., 2019 for specific examples in PTSD). In recent years, the use of polygenic risk 
scores has been validated in disorders such as schizophrenia (International 
Schizophrenia Consortium et al. 2009). More recently, the use of “poly-environmental 
scores” has been proposed (Padmanabhan et al. 2017; Uher & Zwicker 2017). Given 
15 
 
that multiple genetic and non-genetic factors have much greater explanatory power 
than considering them one at a time in most mental disorders (Uher & Zwicker 2017), 
it is likely that “poly-risk” scores (containing both genetic and non-genetic factors) 
improve the prediction of mental disorders. Our data may help developing such scores 
for anxiety and obsessive-compulsive disorders, although the time of exposure and the 
cumulative nature of non-genetic risk will need to be taken into account to improve 
such prediction abilities (Moffitt et al. 2005; Sharma et al. 2016). Developmental 
effects – and their potential interaction with genetic variables- are difficult to study 
using epidemiological data, but they could be investigated using animal models 
(Leonardo and Hen, 2008). 
The majority of factors were only classified as having weak evidence (class IV). 
This mainly reflects the methodological limitations of the data, where less than 5% of 
the factors included more than 1000 cases and where the significance of the 
associations for each individual factor was overall low. The (weak) strength of the 
associations found, together with limitations inherent to the individual study designs 
employed to date, precludes firm causal inferences for any of the significant factors 
identified in our umbrella review (Paulus 2015). Future work to identify 
risk/protective factors could focus on large-scale family-based designs, that allow for a 
more stringent control of unmeasured familial confounders (D’Onofrio et al. 2013) 
and should improve the confidence in the identification of “non-purely genetic” 
risk/protective factors that are in the causal pathway for anxiety and obsessive-
compulsive disorders. For example, recent population-based work in OCD has 
confirmed that a range of perinatal complications are robustly associated with the 
disorder, even after strict control of unmeasured genetic and environmental 
confounders, and that the number of perinatal complications cumulatively contribute 
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to risk for the disorder (Brander et al. 2016b). Similarly, as the field of psychiatric 
genetics is clearly shifting away from the candidate gene approach into the less 
arbitrary genome-wide association studies (GWAS) approach, the identification of 
genetic variants implicated in these disorders should increase dramatically in the next 
few years, as exemplified by the recent formation of an anxiety disorders group within 
the psychiatric genetics consortium (Sullivan et al. 2018). 
We also note that we identified very few protective factors that were not 
reciprocal to risk factors. This indicates that most research so far has focused on 
adverse/negative factors, and highlights another important aspect that will need to be 
addressed in future studies. 
Our results may also offer opportunities for prevention. Current prevention 
programs for anxiety disorders have shown modest benefits (Moreno-Peral et al. 2017) 
and there is a need for new strategies. Our findings lend support to identifying those 
individuals with several risk factors for inclusion in prevention programs (Blanco et 
al. 2014).  Large sets of risk factors of small effects seem to account for the risk for 
anxiety and obsessive-compulsive disorders, and therefore interventions that try to 
modulate several of them concurrently should be devised. For example, parental 
psychopathology and parental rearing styles were significant risk factors for several of 
the disorders investigated here and could be a combined target for prevention efforts. 
Recent data on moderators and mediators of prevention strategies should help optimise 
such efforts (Ginsburg et al. 2015). Our results also support focusing on those 
modifiable risk factors with the largest effects (e.g., trauma), and whose reduction 
would have a greater prospective impact (Li et al. 2016).  Claims of success should 
await the results of randomized trials, since observational associations may not 
necessarily represent causal effects. 
17 
 
Our study has several strengths. We used systematic search methods and both 
the study selection and data extraction were conducted by independent raters. 
Moreover, we assessed that each individual study included in the systematic review or 
meta-analysis fulfilled our inclusion criteria and used standard approaches to assess 
the methodological quality of the systematic reviews or meta-analysis (Fusar-Poli & 
Radua 2018). We offer as supplementary material all data collected in our umbrella 
review. Beyond encouraging open science, this databank may contribute to the 
creation of a database of risk/protective factors for anxiety and obsessive-compulsive 
disorders that can be updated in the future. We also note several limitations. First, we 
assessed each of disorders separately and did not use a mixed “anxiety disorders” 
category as an outcome. There have been changes in the specific disorders included 
under the “anxiety disorders” category, complicating the interpretation of such 
analyses. Second, we collected only information about factors assessed in systematic 
reviews and meta-analyses, and studies not included in this type of publication were 
not eligible for inclusion. Moreover, not all factors were evaluated for all the 
disorders. Third, we did not assess the quality of the individual studies included in the 
systematic reviews and meta-analyses (because this is beyond the scope of an umbrella 
review). Moreover, there may be differences across-studies in the exact definitions and 
methods of assessment for each factor. Finally, the almost ubiquitously limited amount 
of evidence made us explore also what would happen if we removed the need for 
>1000 cases to have highly suggestive evidence. Nevertheless, great caution is needed 
in trusting associations, no matter how strong and consistent, where data are sparse.  
In summary, we found a number of nominally statistically significant risk and 
protective factors for anxiety and obsessive-compulsive disorders, although very few 
were supported by robust evidence. The limited amount of evidence was the main 
18 
 
restricting factor, and this means that there is plenty of room to improve the standards 
of evidence in this field. Our findings may help optimize current prediction models 
and may provide hints for testing prevention strategies.  
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Table 1. Systematic reviews and meta-analyses included in the umbrella review, quality scores, and groups of risk/protective factors examined, by disorder. 
Systematic review/meta-analysis AMSTAR 
score 
(0-11)* 
Groups of risk/protective factors examined Disorders examined 
Brander et al.(2016a) 6 Socio-demographic; parental rearing styles/attachment; substance use; life events; 
other 
OCD 
Brown et al.(2000) 3 Life events Specific phobia, GAD, PD 
Clarner et al. (2015) 8 Life events PD 
Clauss & Blackford (2012) 8 Other (behavioral inhibition in childhood) SAD 
Colonnessi et al. (2011) 8 Parental rearing styles/attachment SAD 
Fernandes et al.(2015) 8 Life events SAD, GAD, PD 
Gariepy et al. (2010) 10 Other (obesity) GAD 
Guo et al. (2016) 10 Socio-demographic Specific phobia, SAD, GAD, PD, OCD 
Jacobson & Newman (2017) 7 Psychopathology  Specific phobia, GAD, PD 
Kedzior et al. (2014) 7 Substance use Specific phobia, GAD, PD, OCD 
Kissely et al.(2017) 11 Socio-demographic SAD, GAD, PD 
Kossowsky et al. (2013) 10 Psychopathology PD 
Kotov et al. (2010) 5 Personality dimensions Specific phobia, SAD, GAD, OCD 
Micco et al. (2009) 7 Parental psychopathology SAD, GAD, PD, OCD 
Moreno-Peral et al.(2014) 9 Socio-demographic; psychopathology; parental psychopathology; personality 
dimensions; substance use; life events; perinatal complications; parental rearing 
styles/attachment; other 
GAD, PD 
Moylan et al. (2012) 6 Substance use  Specific phobia, SAD, GAD 
Osborn et al. (2016) 8 Other (traumatic brain injury) GAD 
Tarricone et al. (2012) 8 Socio-demographic GAD 
Van Steensel et al. (2011) 6 Psychopathology Specific phobia 
*
 Rounded-up average of two raters. 
Note: Some risk/protective factors were assessed only for some of the disorders included in the corresponding systematic review/meta-analysis. 
The specific risk/protective factors assessed in each systematic review or meta-analysis are reported in Table S4 in the supplementary material.  
Abbreviations: AMSTAR- Measurement tool to assess the methodological quality of systematic reviews, GAD-generalized anxiety disorder, PD-panic disorder, OCD-
obsessive-compulsive disorder, SAD-social anxiety disorder. 
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Table 2. Number of systematic reviews and meta-analyses included in the umbrella review, individual studies assessed and included, and potential risk/protective 
factors included in the umbrella review, by disorder. 
 
 
 
 
 
 
 
 
 
Disorder Number of systematic reviews or 
meta-analyses included 
Number of individual studies assessed for 
eligibility 
Number of individual studies 
included 
Number of potential 
risk/protective factors included 
Specific phobia 6 63 19 13 
Social anxiety disorder 10 110 34 20 
Generalized anxiety disorder 13 132 57 110 
Panic disorder 11 144 60 78 
Obsessive-compulsive disorder 6 160 46 206 
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Table 3.  Risk/protective factors showing convincing (class I), highly suggestive (class II), or suggestive (class III) evidence of association with each disorder using the 
original umbrella review criteria or after removing the n>1000 cases criterion, by disorder. 
 
DISORDER FACTOR GROUP RISK / PROTECTIVE FACTOR K N Mea
sure 
ES (95% CI) p PI 
sign. 
I2 ET 
sign. 
ESB 
sign. 
LS 
sign. 
eOR Class Class       
(-n>1000) 
Class       
(-n>1000, 
prosp.) 
SPECIFIC 
PHOBIA 
Socio-demographic Male gender 9 689 OR 0·43 (0·36-0·51) <0·000001 yes 0 % no no yes 0·43 IV I NA 
 Personality dimensions Neuroticism 1 79 g 0·81 (0·57-1·05) <0·000001 NA NA NA no yes 4·35 IV II II 
SAD Psychopathology Dysthymia 1 52 IRR 14·81 (6·7-32·73) <0·000001 NA NA NA no yes 14·81 IV II II 
 Major depression 1 52 IRR 9·35 (4·71-18·54) <0·000001 NA NA NA no yes 9·35 IV II II 
 Personality dimensions Neuroticism 1 89 g 0·89 (0·67-1·12) <0·000001 NA NA NA no yes 5·02 IV II II 
 Life events Early emotional trauma  3 720 OR 2·8 (1·84- 4·24) 0·000001 no 36 % no no yes 2·80 IV III III 
  Early physical trauma  4 1191 OR 2·59 (2·17-3·1) <0·000001 yes 0 no no yes 2·59 I I IV 
  Early sexual trauma  5 1239 OR 3·18 (1·73-5·86) 0·00019 no 85 % no no yes 3·18 III III IV 
 Parental rearing 
styles/attachment 
Insecure attachment in childhood 1 76 g 1·26 (0·91-1·61) <0·000001 NA NA NA no yes 9·83 IV II NA 
 Other Behavioral inhibition in childhood* 7 257 OR 7·52 (3·04-18·61) 0·000013 no 78 % no yes yes 7·52 IV III III 
GAD Socio-demographic Age (30 to 54) 1 390 OR 2·92 (1·78-4·78) 0·000022 NA NA NA no yes 2·92 IV III III 
  Male gender 15 999 OR 0·5 (0·41-0·59) <0·000001 yes 0 % no no yes 0·5 IV I NA 
 Psychopathology Bipolar I disorder 1 390 OR 2·58 (1·48-4·49) 0·00081 NA NA NA no yes 2·58 IV III III 
  Borderline personality disorder 1 390 OR 4·71 (2·93-7·57) <0·000001 NA NA NA no yes 4·71 IV II II 
  History of one psychological disorder 1 288 OR 1·7 (1·27-2·26) 0·00029 NA NA NA no yes 1·70 IV III III 
  Internalizing disorder at age 16 1 288 OR 2·01 (1·34-3) 0·00065 NA NA NA no yes 2·01 IV III III 
  Internalizing disorder at age 7 1 288 OR 1·91 (1·31-2·79) 0·00081 NA NA NA no yes 1·91 IV III III 
  Narcissistic personality disorder 1 390 OR 2·31 (1·49-3·6) 0·00019 NA NA NA no yes 2·31 IV III III 
  Psychological malaise at age 33 1 288 OR 4·73 (3·43-6·52) <0·000001 NA NA NA no yes 4·73 IV II II 
  Schizotypal personality disorder 1 390 OR 2·6 (1·52-4·44) 0·00045 NA NA NA no yes 2·60 IV III III 
  Subsyndromal depression no  distress 1 563 OR 2·25 (1·56-3·24) 0·000014 NA NA NA no yes 2·25 IV III III 
 Parental 
psychopathology 
Anxiety 8 254 OR 3·45 (1·97-6·02) 0·000013 yes 0 % no no yes 3·45 IV III NA 
  GAD without comorbidity 1 106 HR 3·77 (2·27-6·26) <0·000001 NA NA NA no yes 3·77 IV II II 
  Major depression in both parents 1 65 OR 3·7 (2·01-6·79) 0·000024 NA NA NA no yes 3·70 IV III III 
  Major depression in one parent 1 79 OR 2·51 (1·47-4·29) 0·00074 NA NA NA no yes 2·51 IV III III 
 Personality dimensions Behavioral inhibition* 1 106 HR 1·97 (1·66-2·33) <0·000001 NA NA NA no yes 1·97 IV II II 
  Harm avoidance 1 106 HR 1·69 (1·37-2·09) 0·000001 NA NA NA no yes 1·69 IV III III 
 Substance use Cannabis use 1 83 OR 2·79 (1·55-5·02) 0·00059 NA NA NA no yes 2·79 IV III III 
 Life events Early physical trauma  1 350 OR 2·39 (1·92-2·98) <0·000001 NA NA NA no yes 2·39 IV II NA 
  Early sexual trauma  1 350 OR 3·28 (2·6-4·14) <0·000001 NA NA NA no yes 3·28 IV II NA 
  Physical abuse in childhood 1 165 OR 1·82 (1·33-2·48) 0·00017 NA NA NA no yes 1·82 IV III IV 
  Separation events in childhood 1 106 HR 2·44 (1·54-3·85) 0·00013 NA NA NA no yes 2·44 IV III IV 
 Other Received mental health treatment from 
20 to 32 
1 52 OR 6·15 (2·81-13·45) 0·000005 NA NA NA no yes 6·15 IV III III 
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  Received psychiatric medication from 
20 to 32 
1 52 OR 5·19 (1·98-13·55) 0·00078 NA NA NA no yes 5·19 IV III III 
PD Socio-demographic Male gender 11 439 OR 0·5 (0·39-0·64) <0·000001 yes 0 % no no yes 0·5 IV I NA 
 Psychopathology Major depression 2 771 OR 2·03 (1·66-2·49) <0·000001 NA 0 % NA no yes 2·03 IV II II 
  Panic attacks 1 811 OR 2·73 (1·93-3·88) <0·000001 NA NA NA no yes 2·73 IV II II 
  Post-traumatic stress disorder 1 224 OR 2·59 (1·5-4·47) 0·00062 NA NA NA no yes 2·59 IV III III 
  Separation anxiety in childhood 10 880 OR 6·11 (4·31-8·66) <0·000001 yes 5 % no no yes 6·11 IV I NA 
 Parental 
psychopathology 
Panic attacks (for PDA) 1 54 OR 3·93 (1·91-8·07) 0·00019 NA NA NA no yes 3·93 IV III III 
 Substance use Cigarette smoking (daily) 2 201 HR 3·46 (2·21-5·41) <0·000001 NA 21 % NA no yes 3·46 IV II II 
  Cigarette smoking (persistence in daily 
smokers) 
1 51 HR 14·46 (4·81· 43·5) 0·000002 NA NA NA no yes 14·46 IV III III 
  Cigarette smoking (persistence in prior 
daily smokers) 
1 149 HR 3·18 (1·99-5·1) 0·000001 NA NA NA no yes 3·18 IV III III 
 Life events Early emotional trauma  1 123 OR 2·71 (1·57-4·68) 0·00035 NA NA NA no yes 2·71 IV III NA 
  Early trauma  2 194 OR 3·56 (1·86-6·8) 0·00012 NA 0 NA no yes 3·56 IV III NA 
  Early physical trauma  4 449 OR 2·46 (1·95-3·11) <0·000001 yes 0 % no no yes 2·46 IV I III 
  Early sexual trauma  5 518 OR 2·91 (1·67-5·08) 0·00017 no 73 % no no yes 2·91 IV III III 
 Other Joint hypermobility syndrome 1 14 RR 22·34 (5·3-94·29) 0·000023 NA NA NA no yes 22·34 IV III III 
OCD Socio-demographic Paternal age >35 1 122 OR 5·34 (2·15-13·27) 0·00030 NA NA NA no yes 5·34 IV III NA 
 Perinatal complications Ear infection 1 68 OR 57·81 (7·59-440·61) 0·00009 NA NA NA no yes 57·81 IV III NA 
  Early developmental problems 1 13 OR 11·53 (2·84-46·78) 0·00062 NA NA NA no yes 11·53 IV III NA 
  Excess weight gain in pregnancy 1 68 OR 9·31 (2·62-33·1) 0·00057 NA NA NA no yes 9·31 IV III NA 
  Hyperemesis 1 68 OR 8 (3·21-19·97) 0·000008 NA NA NA no yes 8·00 IV III NA 
  Medication during pregnancy 1 68 OR 5·45 (2·6-11·45) 0·000007 NA NA NA no yes 5·45 IV III NA 
  Mumps 1 68 OR 11·41 (3·23-40·28) 0·00015 NA NA NA no yes 11·41 IV III NA 
  Other postnatal problems 1 68 OR 5·81 (2·04-16·52) 0·00096 NA NA NA no yes 5·81 IV III NA 
  Other problems in pregnancy 1 68 OR 12·18 (3·46-42·9) 0·0001 NA NA NA no yes 12·18 IV III NA 
  Throat infection 1 68 OR 4·7 (2·28-9·7) 0·000028 NA NA NA no yes 4·70 IV III NA 
 Substance use Alcohol use disorder 1 105 RR 2·41 (1·6-3·62) 0·000024 NA NA NA no yes 2·41 IV III III 
  Use of cocaine  and  others (no 
marijuana) 
1 105 RR 5·92 (4·97-7·05) <0·000001 NA NA NA no yes 5·92 IV II II 
 Life events Emotional neglect in childhood 1 74 g 0·75 (0·32-1·18) 0·00066 NA NA NA no yes 3·90 IV III NA 
  History of verbal abuse in family 1 33 OR 4·36 (1·88-10·11) 0·00061 NA NA NA no yes 4·36 IV III NA 
  Sexual assault in childhood 2 32 RR 4·03 (1·83-8·87) 0·00052 NA 0 NA no yes 4·03 IV III NA 
 Personality dimensions Neuroticism 1 62 g 1·23 (0·96-1·5) <0·000001 NA NA NA no yes 9·31 IV II II 
 Parental rearing 
styles/attachment 
Interference from father 1 94 g 0·85 (0·55-1·14) <0·000001 NA NA NA no yes 4·67 IV II NA 
  Overprotection from father 6 716 g 0·44 (0·21-0·68) 0·00017 no 65 % no no yes 2·24 III III NA 
  Punishment from father 1 94 g 0·71 (0·42-1) 0·000001 NA NA NA no yes 3·62 IV III NA 
  Refusal from father 1 94 g 1·28 (0·98-1·59) <0·000001 NA NA NA no yes 10·19 IV II NA 
  Warmth from father 3 248 g -0·64 (-0·87- -0·42) <0·000001 no 23 % no no yes 0·31 IV II NA 
 Other Postpartum 1 29 OR 12·05 (3·5-41·52) 0·000081 NA NA NA no yes 12·05 IV III NA 
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Abbreviations: Class – class of evidence, Class (-n>1000)- class of evidence after removing the n>1000 cases criterion, Class (-n>1000, prosp.)– class of evidence after 
removing the n>1000 cases criterion and after sensitivity analyses (including only prospective studies), CI – confidence interval, ES – effect size, ET – Egger test, eOR – 
equivalent odds ratio, ESB – excess significance bias, g – Hedge’s g, GAD – generalized anxiety disorder, HR – hazard ratio, I2 – heterogeneity, IRR – incidence rate ratio, K 
– number of studies for each factor, LS – largest study with significant effect, N – number of cases, NA – not assessable, ns – not significant, OCD – obsessive-compulsive 
disorder, OR – odds ratio, PD – panic disorder, PDA – panic disorder with agoraphobia, PI –  prediction interval, SAD – social anxiety disorder, sign. – significant, RR – 
relative risk.  
* “Behavioral inhibition” referred to “the chronic tendency to respond to novel persons, places, and objects with wariness or avoidant behaviours” in one meta-analysis 
(Clauss & Blackford 2012) and to a personality/character dimension referring to “consistent restraint in response to social and non social situations” in one systematic review 
(Moreno-Peral et al. 2014). 
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FIGURE CAPTIONS 
 
Figure 1. Flow chart of the literature search (see supplementary material for the 
flowcharts for each specific disorder) 
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Figure 2. Forest plots of risk (in red) and protective (in green) factors showing 
convincing (class I) or highly suggestive (class II) evidence of association with each 
disorder, after removing the n>1000 cases criterion.  
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Figure 3. Forest plots of risk/protective factors assessed in at least four of the disorders 
under study and showing convincing (class I) or highly suggestive (class II) evidence of 
association with at least one of the disorders, after removing the n>1000 cases criterion. 
 
 
